Feasibility of sending a direct send HPV self-sampling kit to long-term non-attenders in an organized cervical screening program

被引:4
作者
Sahlgren, Hanna [1 ,2 ]
Sparen, Par [1 ]
Elfgren, Kristina [3 ]
Elfstrom, K. Miriam [4 ,5 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[2] Reg Canc Ctr, Uppsala, Sweden
[3] Dept Clin Sci Intervent, Div Obstet & Gynecol, Stockholm, Sweden
[4] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[5] Karolinska Univ Hosp, Karolinska Univ Lab, Ctr Cerv Canc Prevent, Stockholm, Sweden
关键词
HPV; HPV self sampling; Cervical cancer; Cervical cancer screening; WOMEN; PARTICIPATION; TRIAL;
D O I
10.1016/j.ejogrb.2021.11.430
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction: Non-participation in screening is a main risk factor for cervical cancer. Human-papillomavirus (HPV) self-sampling may be an alternative to repeated invitations for non-attenders. Several studies have concluded that participation among non-attenders increases significantly when offering self-sampling kits for HPV. However, participation rates are highly variable between settings, and therefore pilots to determine optimal implementation strategy have been recommended before routine roll out. Materials and Methods: All women who had not participated in the organized screening program for at least 10 years aged 33-62 in one Swedish county were identified through screening registers. HPV self-sampling kits were sent to all eligible women. Participation was defined as returning a self-sample kit or attending routine screening within 6 months. Women who did not submit the kit within 8 weeks were randomized to receive a written reminder. HPV-positive women were referred directly to colposcopy without prior triage. Biopsies for histopathologic confirmation were used as gold standard. Results: Among eligible women, 150/741 (20.2%) returned the self-sample kit or attended routine screening. A randomized written reminder was sent out to 319/591 non-responders and another 11 women returned the kit. In total, 23/147 (16.3%) of returned kits were HPV positive. Out of the 23 HPV-positive women, 17 (74%) attended colposcopy; 10/17 (59%) had a histopathological high-grade squamous intraepithelial lesions (HSIL) or cervical cancer. The most common HPV type was HPV 52, and 2 out of 3 women with HPV 16 had a histopathologically confirmed cancer. Conclusion: The direct send kit strategy and referral of all HPV-positive women to colposcopy without prior triage appears to be feasible if resources are available and should be prioritized given the high prevalence of HSIL lesions and cancer among non-attenders. A written reminder might further increase attendance. (C) 2021 The Authors. Published by Elsevier B.V.
引用
收藏
页码:68 / 73
页数:6
相关论文
共 43 条
  • [31] Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program
    Arbyn, Marc
    Castle, Philip E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (05) : 769 - 772
  • [32] Acceptability and Feasibility of HPV Self-Sampling as an Alternative Primary Cervical Cancer Screening in Under-Screened Population Groups: A Cross-Sectional Study
    Wong, Eliza Lai-Yi
    Wai-Ling Cheung, Annie
    Wong, Amy Yuen-Kwan
    Chan, Paul Kay-Sheung
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (17) : 1 - 15
  • [33] "The best thing is that you are doing it for yourself" - perspectives on acceptability and feasibility of HPV self-sampling among cervical cancer screening clients in Tanzania: a qualitative pilot study
    Bakiewicz, Aleksandra
    Rasch, Vibeke
    Mwaiselage, Julius
    Linde, Ditte S.
    BMC WOMENS HEALTH, 2020, 20 (01)
  • [34] Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection
    Ernstson, Avalon
    Urdell, Annika
    Forslund, Ola
    Borgfeldt, Christer
    INFECTIOUS AGENTS AND CANCER, 2020, 15 (01)
  • [35] A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program
    Kellen, Eliane
    Benoy, Ina
    Vanden Broeck, Davy
    Martens, Patrick
    Bogers, Jean-Paul
    Haelens, Annemie
    Van Limbergen, Erik
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (04) : 861 - 868
  • [36] “The best thing is that you are doing it for yourself” – perspectives on acceptability and feasibility of HPV self-sampling among cervical cancer screening clients in Tanzania: a qualitative pilot study
    Aleksandra Bakiewicz
    Vibeke Rasch
    Julius Mwaiselage
    Ditte S. Linde
    BMC Women's Health, 20
  • [37] Assessing the feasibility of a rapid, high-volume cervical cancer screening programme using HPV self-sampling and digital colposcopy in rural regions of Yunnan, China
    Goldstein, Andrew
    Goldstein, Lena Sophia
    Lipson, Roberta
    Bedell, Sarah
    Wang, Jue
    Stamper, Sarah A.
    Brenner, Gal
    Goldstein, Gail R.
    O'Keefe, Karen Davis
    O'Keefe, S. Casey
    O'Keefe, McKenna
    O'Keefe, Tierney
    Goldstein, Amelia R.
    Zhao, Anna
    BMJ OPEN, 2020, 10 (03):
  • [38] Increasing participation in cervical cancer screening: Offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial
    Broberg, Gudrun
    Gyrd-Hansen, Dorte
    Jonasson, Junmei Miao
    Ryd, Mare-Liis
    Holtenman, Mikael
    Milsom, Ian
    Strander, Bjorn
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (09) : 2223 - 2230
  • [39] Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial
    Tranberg, Mette
    Bech, Bodil Hammer
    Blaakaer, Jan
    Jensen, Jorgen Skov
    Svanholm, Hans
    Andersen, Berit
    BMC CANCER, 2018, 18
  • [40] The ESSAG-trial protocol: A randomized controlled trial evaluating the efficacy of offering a self-sampling kit by the GP to reach women underscreened in the routine cervical cancer screening program
    Gezels, Eva
    Arbyn, Marc
    Coursier, Patrick
    Devroey, Dirk
    Martens, Patrick
    Simoens, Cindy
    Vaes, Bert
    Van Herck, Koen
    Vankrunkelsven, Patrick
    Verhoeven, Veronique
    Willems, Sara
    CONTEMPORARY CLINICAL TRIALS, 2024, 144